Pharvaris (NASDAQ:PHVS) Cut to Strong Sell at Wall Street Zen

Wall Street Zen cut shares of Pharvaris (NASDAQ:PHVS) from a sell rating to a strong sell rating in a research note issued to investors on Monday.

A number of other research analysts have also issued reports on the company. Wedbush lifted their target price on Pharvaris from $41.00 to $42.00 and gave the company an “outperform” rating in a report on Tuesday, April 7th. Royal Bank Of Canada decreased their target price on Pharvaris from $52.00 to $51.00 and set an “outperform” rating for the company in a report on Monday, April 6th. Wolfe Research started coverage on Pharvaris in a report on Thursday, April 9th. They issued an “outperform” rating and a $42.00 target price for the company. HC Wainwright reiterated a “buy” rating and issued a $60.00 target price on shares of Pharvaris in a report on Tuesday, March 3rd. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Pharvaris in a report on Thursday, January 22nd. Eleven analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $42.73.

Pharvaris Trading Up 1.6%

NASDAQ:PHVS opened at $29.14 on Monday. The firm has a market cap of $1.91 billion, a PE ratio of -8.65 and a beta of -2.58. The stock has a fifty day moving average price of $27.13 and a 200 day moving average price of $25.61. Pharvaris has a 12-month low of $13.44 and a 12-month high of $29.85.

Pharvaris (NASDAQ:PHVS) last released its earnings results on Friday, April 3rd. The company reported ($0.84) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.69) by ($0.15). Equities analysts forecast that Pharvaris will post -2.71 EPS for the current year.

Insider Buying and Selling at Pharvaris

In other news, CEO Berndt Modig sold 23,333 shares of the stock in a transaction dated Thursday, April 9th. The shares were sold at an average price of $27.74, for a total transaction of $647,257.42. Following the completion of the sale, the chief executive officer owned 142,084 shares in the company, valued at approximately $3,941,410.16. This represents a 14.11% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 11.84% of the company’s stock.

Institutional Investors Weigh In On Pharvaris

Several hedge funds have recently made changes to their positions in the business. General Atlantic L.P. boosted its stake in shares of Pharvaris by 6.6% during the third quarter. General Atlantic L.P. now owns 8,031,252 shares of the company’s stock worth $200,380,000 after buying an additional 500,000 shares during the period. Foresite Capital Management IV LLC raised its holdings in Pharvaris by 8.3% during the third quarter. Foresite Capital Management IV LLC now owns 4,778,581 shares of the company’s stock worth $119,226,000 after purchasing an additional 368,000 shares in the last quarter. venBio Partners LLC raised its holdings in Pharvaris by 8.2% during the third quarter. venBio Partners LLC now owns 4,639,304 shares of the company’s stock worth $115,751,000 after purchasing an additional 350,000 shares in the last quarter. Deerfield Management Company L.P. raised its holdings in Pharvaris by 21.1% during the third quarter. Deerfield Management Company L.P. now owns 2,442,464 shares of the company’s stock worth $60,939,000 after purchasing an additional 425,000 shares in the last quarter. Finally, Commodore Capital LP increased its holdings in Pharvaris by 26.5% in the third quarter. Commodore Capital LP now owns 2,418,476 shares of the company’s stock valued at $60,341,000 after buying an additional 507,043 shares in the last quarter.

About Pharvaris

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.